{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T01:40:13Z","timestamp":1729042813303},"reference-count":9,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ad.2024.02.036","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T15:29:10Z","timestamp":1722698950000},"page":"T906-T911","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects"],"prefix":"10.1016","volume":"115","author":[{"given":"M.","family":"S\u00e1nchez-D\u00edaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Fl\u00f3rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Carretero-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Grau-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Garc\u00eda-Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Carrascosa-Carrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.02.036_bib0050","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane database Syst Rev"},{"key":"10.1016\/j.ad.2024.02.036_bib0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.02.036_bib0060","unstructured":"Ministerio de Sanidad del Gobierno de Espa\u00f1a. Documento informativo sobre la financiaci\u00f3n y fijaci\u00f3n de precio de los medicamentos en Espa\u00f1a [accessed 21 Jun 2022] Available from: https:\/\/www.sanidad.gob.es\/profesionales\/farmacia\/pdf\/20220526_Doc_Infor_Financiacion_Med_Esp.pdf"},{"key":"10.1016\/j.ad.2024.02.036_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ad.2019.04.006","article-title":"Treatment Appraisal Reports: Usefulness and Transparency","volume":"111","author":"Puig","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2024.02.036_bib0070","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-D\u00edaz M, Fl\u00f3rez \u00c1, Ara-Mart\u00edn M, Arias-Santiago S, Botella-Estrada R, Ca\u00f1ueto J, et al. Condicionantes de acceso a nuevos medicamentos dermatol\u00f3gicos en Espa\u00f1a: resultados del proyecto EQUIDAD. Actas Dermosifiliogr. doi:10.1016\/j.ad.2023.10.016.","DOI":"10.1016\/j.ad.2023.10.016"},{"key":"10.1016\/j.ad.2024.02.036_bib0075","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/jdv.16564","article-title":"Definition of minimal disease activity in psoriasis","volume":"35","author":"Carretero","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2024.02.036_bib0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjd.14331","article-title":"Evaluating equality in psoriasis healthcare: A cohort study of the impact of age on prescription of biologics","volume":"174","author":"Geale","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.02.036_bib0085","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/bjd.15234","article-title":"Inequalities in access to biological treatments for psoriasis: Results from the Italian Psocare registry","volume":"176","author":"Naldi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2024.02.036_bib0090","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/bjd\/ljac128","article-title":"Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis","volume":"188","author":"Maul","year":"2023","journal-title":"Br J Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024006549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024006549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T01:22:28Z","timestamp":1729041748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024006549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0001731024006549"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.02.036","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.02.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.02.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}